These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12422088)

  • 1. [Current trends and future prospects in biological markers in squamous cell carcinoma of the head and neck].
    Erdamar B; Süoğlu Y; Kiyak E
    Kulak Burun Bogaz Ihtis Derg; 2002; 9(4):301-3. PubMed ID: 12422088
    [No Abstract]   [Full Text] [Related]  

  • 2. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
    Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
    Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma.
    Smardova J; Ksicova K; Binkova H; Krpensky A; Pavlova S; Rottenberg J; Koukalova H
    Oncol Rep; 2004 Apr; 11(4):923-9. PubMed ID: 15010896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of molecular markers and gene profiling in head and neck cancers.
    Gold KA; Kim ES
    Curr Opin Oncol; 2009 May; 21(3):206-11. PubMed ID: 19346943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Galectins in squamous cell carcinomas of the head and neck cancers].
    Cada Z; Plzák J; Chovanec M; Dvoránková B; Lacina L; Szabó P; Smetana K; Betka J
    Cas Lek Cesk; 2008; 147(11):559-63. PubMed ID: 19097359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
    Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bibliography. Current world literature. Head and neck.
    Curr Opin Oncol; 2000 May; 12(3):B92-104. PubMed ID: 10841203
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
    Buffa FM; Bentzen SM; Daley FM; Dische S; Saunders MI; Richman PI; Wilson GD
    Clin Cancer Res; 2004 Jun; 10(11):3745-54. PubMed ID: 15173081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium.
    Farshadpour F; Hordijk GJ; Koole R; Slootweg PJ
    J Oral Pathol Med; 2008 Oct; 37(9):549-54. PubMed ID: 18331287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
    van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
    J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary re: Q-T Le et al, identification of osteopontin as a prognostic marker for head and neck squamous cell carcinomas. clin cancer res, 9: 31-32, 2003.
    Denhardt DT
    Clin Cancer Res; 2003 Jan; 9(1):31-2. PubMed ID: 12538448
    [No Abstract]   [Full Text] [Related]  

  • 15. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
    Taguchi T; Kato Y; Baba Y; Nishimura G; Tanigaki Y; Horiuchi C; Mochimatsu I; Tsukuda M
    Oncol Rep; 2004 Feb; 11(2):421-6. PubMed ID: 14719078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora sheds light on head and neck squamous cell carcinoma.
    Han H; Von Hoff DD
    Clin Cancer Res; 2006 Sep; 12(17):5003-4. PubMed ID: 16951211
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrence in head and neck squamous cell carcinoma. Editorial.
    Leibowitz MS; Ferris RL
    Cancer; 2008 Aug; 113(4):671-3. PubMed ID: 18536028
    [No Abstract]   [Full Text] [Related]  

  • 18. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
    Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
    Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
    Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
    Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of metalloproteins in the clinical management of head and neck squamous cell carcinoma.
    Scurry WC; Stack BC
    Head Neck; 2007 Dec; 29(12):1144-55. PubMed ID: 17657798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.